Inactivation of the tumor suppressor Rb in the mouse induces cell death, which depends entirely (in lens, CNS) and only partly (PNS, skeletal muscles) on Apaf1/Ced4, an apoptosomal factor thought to be required for processing procaspase-9 following mitochondrial permeabilization. Here, we report that in response to cytotoxic drugs, Apaf1 À/À primary myoblasts but not fibroblasts undergo bona fide apoptosis. Cell demise was associated with disruption of mitochondria but not endoplasmic reticulum. Processing of procaspase-9 occurred in Apaf1 À/À myoblasts but not fibroblasts, and ablation of Casp9 prevented drug-induced apoptosis in both cell types. Deregulation of the Rb pathway by overexpression of E2F1 also induced caspase-9-dependent, Apaf1-independent apoptosis in myoblasts. Despite its requirement for apoptosis in vitro, mutation in Casp9 abrogated cell death in the nervous system and lens but only partly in skeletal muscles of Rb-deficient embryos. In addition, developmental cell death in fetal liver and PNS was not inhibited in Casp9 À/À embryos. Therefore, loss of pRb elicits apoptosome-dependent and apoptosome-independent cell death, and the requirement and coupling of caspase-9 to Apaf1 are both context-dependent.
Introduction
Inactivation of the Rb tumor suppressor pathway represents one of the hallmarks of cancer progression (Classon and Harlow, 2002; Zacksenhaus, 2003) . In different tumors, Rb is often mutated or its protein product (pRb) is functionally inactivated primarily by phosphorylation (Sherr, 2000) . pRb binds certain transcription factors such as E2F1 and modulates the expression of genes involved in S phase progression and DNA synthesis as well as cell death (Nahle et al, 2002; Chau and Wang, 2003) . In the course of cancer progression, loss of pRb coincides with inactivation of proapoptotic factors, such as p53 (Classon and Harlow, 2002) . However, the exact apoptotic pathways that are induced in response to Rb inactivation during development and cancer progression are not fully understood.
Rb knockout mice provide an excellent model to study survival pathways downstream of pRb. Mutation in Rb leads to mid-gestational death with massive apoptosis, ectopic DNA synthesis and incomplete differentiation in tissues where Rb is highly expressed (Lipinski and Jacks, 1999; Vooijs and Berns, 1999) . This includes the developing nervous system (both PNS and CNS), liver, lens and muscles (Jiang et al, 1997) . Rb À/À embryos expressing an Rb minitransgene, mgRb, in the nervous system survive to term and reveal a required role for pRb in terminal myogenesis (Zacksenhaus et al, 1996; Jiang et al, 2001) . Developing muscles in mgRb:Rb À/À fetuses exhibit cell death, reduced muscle mass, endoreduplication in residual myotubes and decreased expression of certain muscle markers (Zacksenhaus et al, 1996; Jiang et al, 2000) . Placental rescue or conditional inactivation of Rb in the E6.5 embryo proper also extends the life span of Rb-null embryos to birth and reveals similar muscle defects (MacPherson et al, 2003; Wu et al, 2003) . Hence, apoptosis in certain tissues (CNS) appears to result from the combined effects of pRb loss and external stress, whereas apoptosis in other tissues (lens, skeletal muscles) seems to be cell autonomous. Two major apoptotic pathways have been described: the intrinsic mitochondrial pathway and the extrinsic death ligand pathway. In the latter, death ligands such as TNFa induce trimerization of death receptors, activation of apical caspase-8 and subsequently executioner caspases, such as caspase-3 (Ricci et al, 2003) . In the intrinsic pathway, DNA damage, hypoxia, cytotoxic drugs or oncogene activation leads to mitochondrial outer membrane permeabilization (MOMP) and release of apoptogenic factors. One such factor, cytochrome c, binds Apaf1 (apoptosis protease activating factor-1) and promotes oligomerization and recruitment of apical procaspase-9 into a high-molecular-weight complex termed the apoptosome (reviewed in Ricci et al, 2003) . Assembly of the apoptosome induces autoprocessing of caspase-9 and subsequent activation of caspase-3. Null mutations in Apaf1 or Casp9 lead to similar phenotypes (Cecconi et al, 1998; Hakem et al, 1998; Kuida et al, 1998; Yoshida et al, 1998) . Most Apaf1 À/À and Casp9 À/À mice survive to embryonic day (E) 16.5 and exhibit severe brain abnormalities due to suppression of apoptosis and accumulation of neurons. Several other organs are also affected (e.g. lens, interdigital webs). In addition, both Apaf1 À/À and Casp9 À/À primary fibroblasts resist apoptosis and cooperate with Myc in promoting neoplastic transformation (Soengas et al, 1999) .
Genetic analysis of Rb À/À embryos indicates that in the CNS and lens, cell death can be mitigated by concurrent inactivation of E2F1 or p53 (Morgenbesser et al, 1994; Macleod et al, 1996; Tsai et al, 1998; Jiang et al, 2000) . In contrast, apoptosis in PNS and skeletal muscles is independent of these factors. Intriguingly, inactivation of Apaf1 completely suppresses cell death in the CNS and lens of Rb mutant embryos, but only partly rescues the PNS and skeletal muscles (Guo et al, 2001) . To elucidate this Apaf1-independent cell death, we herein investigated mechanisms of apoptosis in Apaf1 À/À primary myoblasts. We found that Apaf1 is dispensable for apoptosis induced by cytotoxic drugs or overexpression of E2F1 in primary myoblasts but not fibroblasts, whereas caspase-9 is required in both cell types. Despite its critical role in apoptosis in vitro, caspase-9 mediated cell death in only certain cell types in Rb mutant embryos, excluding skeletal muscles. Thus, the coupling of caspase-9 activation to Apaf1 in response to identical apoptotic stimuli and the requirement for the apoptosome as a whole are both cell-type-specific.
Results
Primary myoblasts lacking Apaf1 retain sensitivity to cytotoxic drugs Primary myoblasts were isolated from limbs of four independent Apaf1 À/À mutant embryos exhibiting obvious brain protrusion and used within passage 2-4 (Supplementary Figure S1A and B). The percentage of myoblasts was estimated to be over 90% based on immunostaining for Desmin, a myoblast marker (Supplementary Figure S1D) . Both wildtype and Apaf1 À/À primary myoblasts were able to differentiate into multinucleated myotubes and express myosin heavy chain (MHC) ( Figure 1A ), myogenin and Troponin T (not shown). The response of Apaf1 À/À primary myoblasts to cytotoxic drugs was determined by the MTT assay, which detects mitochondrial activity, and hence cell proliferation and viability. Treatment of normal mouse embryonic fibroblasts (MEFs) or myoblasts (MEMs) with staurosporin (STS) reduced cell viability in a concentration-and time-dependent manner ( Figure 1C and D). Whereas Apaf1 À/À MEFs were highly resistant, Apaf1 À/À MEMs were almost as sensitive to STS as control cells. The residual resistance to STS in Apaf1 À/À mutant MEMs might reflect low contamination with primary fibroblasts or some nonredundant requirement for Apaf1. The kinetics of mitochondrial inhibition with other drugs such as cisplatin (CP) was much slower; substantial reduction in MTT levels was observed only after 16-24 h ( Figure 1E ). Apaf1 À/À MEFs were consistently more resistant to doxorubicin and etoposide relative to control MEF; whereas both wild-type and Apaf1 À/À MEMs were sensitive.
However, with the latter drugs, the levels of cell viability in both myoblast cultures fluctuated in different experiments (data not shown). We therefore used STS in most subsequent experiments. TNFa, which initiates apoptosis via the extrinsic pathway, suppressed cell viability in all cell types irrespective of Apaf1 ( Figure 1F ). Thus, the persistent cell death previously observed in skeletal muscles of Rb-Apaf1 double mutant embryos can be recapitulated in primary Apaf1 (Figure 2A) . Strikingly, Apaf1 À/À MEMs apoptosed at a similar rate as control MEMs ( Figure 2B ). On average, the levels of apoptosis in four different sets of Apaf1 À/À MEMs and control myoblasts were 29.6% and 24.9%, respectively ( Figure 2C ). To test whether cell death in Apaf1 À/À myoblasts involved DNA fragmentation, we employed the Terminal-deoxynucleotidyl-transferase (TdT)-mediated dUTP Nick End-Labeling (TUNEL) assay (Gavrieli et al, 1992) . Wild-type MEFs were sensitive to CP or STS treatments, whereas Apaf1 À/À MEFs were resistant ( Figure 2D Figure 2E ). Caspase-3 itself was processed in both controls and Apaf1 À/À MEMs (Supplementary Figure S2A) .
Ultrastructural analysis revealed that STS treatment induced typical chromosomal condensation, seen as large dense material in the nucleus in both control and Apaf1 Figure S3) . Mitochondrial swelling and loss of cristae were also detected in Apaf1 À/À myoblasts and control cells but not in Apaf1 À/À fibroblasts ( Figure 2F , white arrowheads;
Supplementary Figure S3 ). Taken together, cytotoxic drugs can induce classical caspase-dependent apoptosis in Apaf1
myoblasts in a manner that is indistinguishable from control myoblasts or fibroblasts.
Mitochondrion but not endoplasmic reticulum is implicated in apoptosis induced in Apaf1 À/À myoblasts
In addition to the mitochondria, apoptosis can be induced by other organelles such as the endoplasmic reticulum (ER) (Ferri and Kroemer, 2001) . ER stress leads to Ca þ 2 -dependent induction of MOMP as well as direct activation of procaspase-9 by ER-bound caspase-12 (Rao et al, 2002) . To test whether STS induces apoptosis in myoblasts via the ER, we examined the expression of chaperone Bip/Grp78, which is transcriptionally activated upon ER stress. Thapsigargin (TG), a known inducer of ER stress via specific inhibition of sarcoplasmic/ER Ca þ 2 -ATPase (SERCA) (Lytton et al, 1991) , stimulated Bip expression 2-4-fold in wild-type MEFs, MEMs and Apaf1 À/À MEMs ( Figure 3A and B). In contrast, STS treatment moderately inhibited Bip expression relative to untreated cells, indicating that this drug does not induce ER stress in primary myoblasts.
In untreated cells, cytochrome c was localized in mitochondria as evident from a characteristic filamentous and overlapping staining with a mitochondrial specific marker (mito-tracker) ( Figure 3C ). Following STS treatment, cytochrome c staining became more uniform and distinct from the mito-tracker marker, indicative of mitochondrial release. Cytochrome c release appeared in both fibroblasts and myoblasts, irrespective of the presence of Apaf1, and was unlikely the consequence of apoptosis as it was observed immediately 1 h post-STS treatment. Cyclosporine A (CsA), an inhibitor of MOMP (Ricci et al, 2003) , suppressed cytochrome c release in all cultures ( Figure 3C ).
We then asked whether inhibition of cytochrome c release by CsA was associated with suppression of cell death in Apaf1 À/À MEMs. Remarkably, cotreatment of control MEFs, MEMs and Apaf1 À/À MEMs with STS and CsA reduced the level of apoptosis by approximately 50%, compared to drug treatment alone ( Figure 3D ). CsA did not attenuate TGinduced apoptosis ( Figure 3D ). Although Apaf1 À/À MEFs were resistant to apoptosis initiated by STS, they readily apoptosed in response to TG. Collectively, these results implicate the mitochondrion or another CsA-sensitive organelle, but not the ER, in mediating Apaf1-independent cell death in skeletal myoblasts.
Cytotoxic drugs induce processing of caspase-9 in Apaf1
À/À primary myoblasts
The suppression of apoptosis by CsA in Apaf1 À/À mutant myoblasts inspired us to ask whether apoptosis was accompanied by caspase-9 activation, independently of Apaf1. 
Casp9
À/À and control MEMs cultured in 'Growth' or 'Differentiation' conditions, stained for MHC (cytoplasm-green) and counterstained with Hoechst (nucleus-blue). Bar ¼ 50 mm. (C-F) Representative MTT assays performed in duplicate on primary cultures treated with increasing concentrations of STS (C), using 2 mM STS for different duration (D); 50 mM CP (E); or 2 mM TNFa (F).
Apoptosome assembly induces autocleavage of procaspase-9, a 49 kDa protein, into 37, 35, 12 and 11 kDa proteins (Li et al, 1997) . Caspase-3 further amplifies caspase-9 activity by cleaving procaspase-9 into 37 and 12 kDa fragments (Fujita et al, 2001) . In fibroblasts treated with doxorubicin or STS, processed forms of caspase-9 were observed only in the presence of Apaf1 ( Figure 4A and B). By contrast, in myoblasts, procaspase-9 was efficiently processed in response to these drugs irrespective of Apaf1 ( Figure 4A and B). A doublet of p37 and p35 kDa proteins corresponding to the cleaved forms of caspase-9 was clearly detected in drug-treated wild-type and Apaf1 À/À myoblasts. As the p35 fragment is generated only by caspase-9 autocleavage, this observation suggests that autoprocessing of caspase-9 occurred independent of Apaf1 and caspase-3. Processing of procaspase-9 in Apaf1 À/À MEMs was further confirmed using a caspase-9 antibody that recognizes only the p35 active form of caspase-9. Both STS and etoposide, but not TNFa, induced the formation of p35 caspase-9 (Supplementary Figure S2B) . Since TNFa induced myoblasts cell death ( Figure 1F ) without activating caspase-9, the cleavage of procaspase-9 in Apaf1 À/À myoblasts in response to cytotoxic drugs likely reflects a direct effect of STS rather than an indirect consequence of apoptosis.
To ascertain that processing of procaspase-9 was accompanied by increased enzymatic activity, we assayed the cleavage of LEHD-AMC, a synthetic fluorogenic substrate of caspase-9 ( Figure 4C ). Lysates from STS-treated Apaf1
MEFs yielded a very low signal. In contrast, Apaf1
À/À MEMs exhibited a high level of caspase-9 activity similar to control MEFs and MEMs. The caspase-9 inhibitor LEDH-CHO suppressed this activity. Thus, procaspase-9 can be processed and rendered biologically active in skeletal myoblasts in the absence of Apaf1.
Caspase-9 is required for apoptosis in primary myoblasts
We next investigated whether caspase-9 was not only processed but also required for apoptosis in Apaf1 À/À myoblasts.
First, we tested the effect of specific caspase inhibitors on apoptosis in the various cell types (Supplementary Figure  S2C) . The caspase-8 inhibitor (Z-IETD-FMK), which abrogates death ligand-mediated apoptosis, had a minimal to marginal effect on cell death in the different cell types. Conversely, caspase-3 (Z-VAD-fmk) and caspase-9 (AC-LEHD-CHO) inhibitors significantly suppressed apoptosis in both control and Apaf1 À/À myoblasts.
To corroborate these results, we generated caspase-9-deficient myoblasts from five E16.5 Casp9 À/À null embryos and control littermates (Figure 1B ; Supplementary Figure 1C) . While B40% of wild-type MEMs died by apoptosis, Casp9 À/À myoblasts were dramatically resistant (B0.15%) ( Figure 5A and B) . TUNEL analysis also revealed 15% positive nuclei in control MEMS but only 0.18% in Casp9 À/À myoblasts ( Figure 5C ). Processing of caspase-3 (Supplementary Figure S2A) and PARP ( Figure 5D ) was completely inhibited in Casp9 À/À myoblasts treated with STS, whereas TNFa-induced processing of PARP was unaffected. Induction of apoptosis by TG was also dependent on caspase-9, even though Apaf1 was dispensable ( Figure 3D ). Thus, caspase-9 is required for apoptosis induced by cytotoxic drugs in both myoblasts and fibroblasts. However, activation of capsase-9 can be uncoupled from Apaf1 in response to cytotoxic drugs in myoblasts or ER stress in both cell types.
Uncoupling of caspase-9 activation from Apaf1 in myoblasts occurs as a result of deregulation of the pRb pathway We next asked whether the differential roles of Apaf1 and caspase-9 in myoblasts and fibroblasts in response to cytotoxic drugs could be extended to apoptosis induced by the deregulation of Rb. suggest that caspase-9 mediates apoptosis downstream of pRb, the low levels of apoptosis in myoblasts precluded conclusive interpretation.
To circumvent this problem, we induced cell death by overexpressing E2F1 using an adenovirus vector in which E2F1 is fused to green fluorescent protein (GFP; Ad.E2F1-GFP; Gill and Hamel, 2000) . Previous analysis established that overexpression of E2F1 in primary myoblasts results in similar defects as loss of pRb, except that the level of apoptosis is markedly higher . Following Ad.E2F1-GFP infection, GFP-positive cells were gated and tested for apoptosis by PE-conjugated AnnexinV assay (red). In agreement with previous studies (Moroni et al, 2001) , apoptosis induced by E2F1 was reduced from approximately 35% in control MEFs to B4.5% in Apaf1 À/À fibroblasts ( Figure 6B ). However, in myoblasts, apoptosis was only reduced from 36 to 20% in the absence of Apaf1, but to B6% in the absence of caspase-9. Thus, both cytotoxic drugs and deregulation of the pRb pathway induce caspase-9 activation independently of Apaf1 in primary myoblasts in vitro.
Mutation in Casp9 only partly inhibits cell death in skeletal muscles of mgRb:Rb À/À mutant fetuses
The observation that caspase-9 was important in myoblasts in vitro even in the absence of Apaf1 prompted us to test whether this caspase was also required for the Apaf1-independent apoptosis that occurs during aberrant myogenesis in mgRb:Rb À/À mutant fetuses (Guo et al, 2001) . To address this issue, we generated E16.5 mgRb:Rb À/À :casp9 À/À composite mutant fetuses (Table I) . As previously noted for mgRb:Rb skeletal myotubes contained giant nuclei indicative of endoreduplication and were shorter and less abundant relative to wild-type muscles, suggesting widespread cell death (not shown).
To determine the effect of caspase-9 loss on apoptosis in mgRb:Rb À/À embryos, mutant and control mice were subjected to in situ TUNEL analysis (Figure 7) . The level of cell death detected by the TUNEL assay varied substantially in different areas and different sections from the same tissue (i.e. DRG, muscles). These variations were observed in multiple experiments performed in parallel and probably reflected genuine fluctuations in apoptosis rather than technical inconsistencies. To overcome this problem, we performed TUNEL assays on serial sections across different areas from six sets of double mutants, single mutants and control littermates. A total of 86 and 174 sections of E13.5 and E16.5 embryos, respectively, were analyzed in the experiments described below. As previously established, mgRb:Rb À/À fetuses exhibited widespread cell death during terminal myogenesis ( Figure 7A ) (Zacksenhaus et al, 1996) . Strikingly, loss of caspase-9 only moderately reduced the level of cell death in mgRb:Rb 
Caspase-9 is required for apoptosis in CNS, partly in PNS but not in liver
To determine the role of caspase-9 in cell death in the CNS and PNS of Rb null embryos, we generated E13.5 Rb À/À :Casp9 À/À double mutant embryos lacking the mgRb mini-gene (Table I ). In the CNS, very few TUNEL-positive nuclei were detected in control and Casp9 À/À mutant embryos, whereas in Rb À/À embryos, extensive cell death was observed in the postmitotic zone throughout the spinal cord and brain ventricles ( Figure 7B ). Loss of caspase-9 dramatically inhibited cell death in the CNS of Rb À/À :Casp9 À/À mutant embryos ( Figure 7B ). Contrary to the CNS, moderate levels of cell death were observed in the PNS of control and Casp9 À/À embryos ( Figure 7B ). This indicates that caspase-9 is not required for developmentally regulated cell death in the PNS. The low level of cell death in the PNS varied from section to section and was most evident in trigeminal ganglia ( Figure 7B ). In dorsal root ganglia, only 1-6 nuclei were typically observed in different sections (not shown). The level of apoptosis in the PNS increased dramatically in Rb À/À embryos ( Figure 7B ).
Concomitant loss of pRb and caspase-9 reduced cell death to levels seen in control and Casp9 À/À embryos, but was not completely inhibited as in the CNS ( Figure 7B ). Moderate levels of cell death were also found in the developing livers of Rb
mutant embryos ( Figure 7C ) and control animals (not shown). We conclude that loss of caspase-9 inhibits aberrant cell death induced in Rb-mutant CNS and PNS, but not physiological cell death in the developing PNS and liver.
Discussion

Diverged apoptotic pathways downstream of pRb
We report that inactivation of the tumor suppressor Rb elicits apoptosome-dependent and apoptosome-independent apoptotic pathways. Data presented in Figure 7 and previously (Macleod et al, 1996; Jiang et al, 2000; Guo et al, 2001) , indicate that mutation in Rb results in a p53-Apaf1-caspase-9-dependent cell death in the CNS and lens, but p53-Apaf1-caspase-9-independent death in skeletal muscles. The persistent cell death observed in skeletal muscles in the absence of Apaf1 (Guo et al, 2001) or caspase-9 (Figure 7 ) suggests the existence of alternative apoptotic pathways that can bypass the apoptosome and induce classical apoptotic death (TUNEL-positive). Mutation in Rb may render myoblasts insensitive to survival factors (Ostrovsky and Bengal, 2003) or hypersensitive to death ligands (e.g. TNFa) that can induce apoptosis independent of the mitochondria ( Figures 1F and  5D ) (Phillips et al, 1999; Chau et al, 2002) . In the PNS, we observed a moderate level of cell death both in wild-type and Casp9 À/À embryos ( Figure 7B ). This indicates that the requirement for caspase-9 can be circumvented by death stimuli generated during normal development of peripheral neurons. However, the excessive apoptosis seen in Rb mutant PNS is suppressed in Rb À/À :Casp9 À/À mutant embryos to levels comparable to control and Casp9 À/À mutant mice. We previously showed that mutations in Apaf1 reduce but do not completely inhibit cell death in the PNS of Rb null embryos (Guo et al, 2001 ). Thus, activation of procaspase-9 in the PNS is mediated partly by Apaf1 and partly by an unknown factor/ mechanism. Apoptosis induced during neurogenesis but not hematopoiesis in Bcl-xL knockout embryos (Motoyama et al, 1995) can be mitigated by concurrent inactivation of Apaf1 . Mutation in Casp9 also inhibits apoptosis in Bcl-xL À/À neurons (Zaidi et al, 2001 ). Thus, inactivation of the apoptosome has similar effects on Rb À/À and Bcl-xL À/À embryos, with the exception that in our hand some apoptotic cells are observed in the Rb
and Rb
À/À
:Casp9 À/À PNS. In accordance with recent studies in vitro (Deverman et al, 2002) , these observations indicate that pRb and Bcl-xL operate in a common survival pathway at least in certain tissues. Figure S2 ). The latter is consistent with previous findings that link DNA damage to induction of E2F1 via ATM (Lin et al, 2001) . Uncoupling of the apoptosome has been observed in Sendai virus-infected cells (Bitzer et al, 2002) or following activation of other cellular organelles like the ER (Figure 3 and Rao et al, 2002) , but not by cytotoxic drugs or deregulation of E2F1 as reported here.
What then triggers the processing of caspase-9 in Apaf1 À/À myoblasts? One possible mechanism, which we began to explore, is that in myoblasts, cytotoxic drugs exert their effect through other organelles, in addition to mitochondria. Although the ER is unlikely to be activated by STS (Figure 3 ), other organelles may engage procaspase-9 in response to cytotoxic drugs. Noncaspase related factors such as DCC may also target caspase-9 (Forcet et al, 2001) . Our observation that CsA suppresses apoptosis in Apaf1
À/À myoblasts ( Figure 3 ) directly implicates the mitochondrion. Myoblasts and peripheral neurons may efficiently release mitochondrial apoptogenic factors (e.g. Smac/Diablo) that may facilitate the autoprocessing of caspase-9 even in the absence of Apaf1, as previously suggested (McNeish et al, 2003) . A complication in testing this possibility is that smac/ diablo null mice develop normally, indicating that this IAP inhibitor plays a redundant role, possibly with HtrA2/Omi . It is also possible that an Apaf1-like molecule compensates for the loss of Apaf1 in these tissues. Several Apaf1-like factors with CARD, NOD and a leucinerich repeat in place of the WD domain have been identified (Inohara and Nunez, 2003) . However, there is no evidence for the existence of a genuine Apaf1-like protein, comprising CARD, NOD and WD repeats, in the human genome (Aravind et al, 2001) . Further research may elucidate the mechanism by which cytotoxic drugs and E2F1 induce procaspase-9 processing in Apaf1 À/À primary myoblasts, and may unravel novel therapeutic targets for treating muscle atrophies and other degenerative diseases.
Context-specific requirement for the apoptosome
Mutations in Apaf1 and Casp9 clearly inhibit physiological as well as Rb À/À -induced cell death in the developing CNS ( Figure 7 ) Yoshida et al, 2002) . Inactivation of these apoptosomal factors also impedes apoptosis in reconstituted thymocytes and splenocytes in response to some but not all stimuli. Notably, Apaf1 is dispensable for the negative selection of thymocytes , indicating that in contrast to the response to cytotoxic drugs in vitro, alternative pathways mediate developmental cell death in vivo. This is in agreement with our observation of persistent apoptosis in fetal livers of Casp9 À/À and Apaf1 À/À mutant embryos ( Figure 7C ). Importantly, promoter silencing and mutations in Apaf1 were identified in melanoma (Soengas et al, 2001 ) and other types of tumors (reviewed in Yoshida, 2003) , implicating this factor as a critical player downstream of MOMP in these cell types in the course of cancer progression. On the other hand, Apaf1 À/À ES and neuronal cells treated with certain cytotoxic drugs exhibit protracted cell death but ultimately die by Bcl2-suppressible and AIF-mediated pathways in vitro (Haraguchi et al, 2000; Cregan et al, 2002) . Here, we showed that the coupling of caspase-9 to Apaf1 and the role of the apoptosome as a whole are both context-dependent. Given this diversity, it is becoming apparent that distinct pathways are activated to execute cell demise depending on the tissue, developmental stage and apoptotic stimuli.
Implications for therapy
Previous analysis of Rb À/À :Casp3 À/À mutant embryos revealed that caspase-3 is required for apoptosis in the PNS but not the CNS (Simpson et al, 2001) . Our observation of caspase-9-dependent apoptosis in the CNS ( Figure 7B ) implicates other executioner caspases, such as 2, 6 and 7 expressed in the CNS, as mediators of apoptosis downstream of caspase-9 in these neurons. Taken together, caspase-9 may provide a target of choice for chemoprevention of injured neurons in the nervous system. Likewise, the complete inhibition of apoptosis in the lens of Rb À/À :Casp9 À/À mutant embryos ( Figure 7B ) suggests that inhibitors to this apical caspase may impede lens degenerative diseases.
Materials and methods
Isolation, culturing and Adnoviral infection of primary myoblasts and fibroblasts
Limb muscles from E16.5 fetuses were incubated in 0.25% trypsin/ EDTA and 300 units/ml collagenase II (Sigma) at 371C for 30 min, dispersed by repeated tituration with Pasteur pipettes and cultured in growth media (GM; 1:9 DMEM:HAM-F10 media (Sigma), 20% FBS (Hyclone)). Myoblasts were further enriched by differential plating. Briefly, cells were seeded onto poly-L-lysine (Sigma)-coated plates to allow contaminating fibroblasts to adhere for 30 min at 371C; myoblasts remaining in media suspension were collected and used by passage 4. Control fibroblasts were isolated from the skin of the same embryos. To induce differentiation, myoblasts were allowed to reach confluency on gelatin-coated plates in GM and then switched to differentiation media (DM; HAM-F10, 2% horse serum and 10 mg/ml insulin). Ad.E2F1-GFP was propagated in 293 cells as described (Gill and Hamel, 2000) .
MTT assay
A total of 5000 cells/well were seeded into 96-well plates and grown overnight. After drug treatment, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide in PBS, Sigma) was added to 1 mg/ml for 2 h at 371C, followed by 100 ml of extraction buffer (20% (w/v) SDS, 50% N,N-dimethylformamide, 20% acetic acid and 2.5% 1 N HCl, pH 4.7) overnight. Colorimetric reading at 570 nm was performed using a microplate reader (Molecular Devices).
Western blotting, immunohistochemistry, confocal and electron microscopy Detailed procedures are available upon requests. For Western blots we used anti-mouse-specific caspase-9 polyclonal antibody (1:1000 dilution; New England Biolabs) and anti-p35 caspase-9 polyclonal antibody (1:200 dilution, SantaCruz) followed by anti-rabbit IgGhorseradish peroxidase (HRP)-conjugated secondary antibody (1:2000 dilution; New England Biolabs). Similar results were obtained using anti-caspase-9 antibody provided by Dr X Wang (Li et al, 1997) (not shown). Additional antibodies included rabbit anti-parp (1:1000 dilution; New England Biolabs), rabbit anti-Bip/ Grp75 (1:200 dilution; SantaCruz), goat anti-Apaf1 (1:1000 dilution; Upstate); goat anti-Fast skeletal Troponin T (1:100 dilution; SantaCruz), rabbit anti-myogenin (1:200 dilution; SantaCruz) and monoclonal anti-a-tubulin antibody (1:1500 dilution; Sigma). HRP activity was detected with SuperSignal West Dura chemiluminescence (Pierce) and captured by a Nikon CCD camera via BioRad Flour-S-Max Multimager.
For cytochrome c labeling, cells on coverslips were incubated with mitotracker Red 580 (200 nM, Molecular probes), fixed with 100% methanol at À201C for 5 min and blocked for 5 min in 1% BSA. Monoclonal anti-cytochrome c antibody (1:50 dilution, SantaCruz) and Alexa 488 (1:100 dilution) goat anti-rabbit secondary antibody were added for 45 min each. Anti-myosin heavy chain (MHC; Sigma-Aldrich, MI) and anti-desmin (SantaCruz, CA) were used at 1:20 dilution. Confocal images were captured at 0.5 mm optical section using a 63 Â c-apochromat objective lens and an LSM 510 Zeiss Axiovert 100M confocal microscope. Electron micrographs were taken with Hitachi H600 transmission electron microscope.
AnnexinV and TUNEL assays on single cells
AnnexinV and propidium iodide (PI) assays were performed using FITC-, GFP-or PE-AnnexinV kits (BD Biosciences, San Jose, CA) and quantified with a FACSCalibur flow cytometer (BD Biosciences). In all, 10 000 events were counted for each sample. For TUNEL, 2 Â10 6 STS-treated or control cells were fixed in 4% paraformaldehyde for 5 min followed by 1 min of 0.1% trypsin digestion. After two washes in PBS, cells were treated with terminal deoxynucleotidyl transferase (100 U/ml, Boeringer, Mannheim) and 10 mM fluorescein-dUTP (Boeringer, Mannheim) at 371C for at least 1 h. Cells were washed twice in PBS and subjected to flow cytometry analysis.
Caspase-9 activity and caspase inhibition analyses
In vitro caspase-9 activity was assayed according to the ApoAlert Caspase-9 kit (Clontech) using a GENios fluorometer (Tecan) with 380 nm excitation and 460 nm emission. Caspase inhibitors (100 mM, SantaCruz) were incubated with 2 mM STS for 4 h and analyzed by AnnexinV/PI assay. embryos were obtained from timed pregnancies of heterozygous intercrosses. Duplicate tissues were isolated from each embryo for genotyping. PCR conditions have been described previously (Zacksenhaus et al, 1996; Hakem et al, 1998; Yoshida et al, 1998) .
Breeding and genotyping
Histology and TUNEL analysis on sections
Briefly, embryos were fixed in 4% paraformaldehyde/PBS at 41C overnight, embedded in paraffin and sectioned (8 mm). H&E and TUNEL assays, using biotin-dUTP, followed by DAB staining were performed as described (Jiang and Zacksenhaus, 2002) .
Supplementary data
Supplementary data are available at The EMBO Journal Online.
